Aurora Cannabis Denies Acquisition of MedLeaf Therapeutics

Aurora Cannabis has officially denied recent rumors regarding its acquisition of New Zealand-based MedLeaf Therapeutics, clarifying that it has neither entered into any agreement nor engaged in discussions about such a transaction. The company emphasized that any official disclosures, including its financial statements for Q4 and fiscal year 2025, are available on its website and regulatory platforms SEDAR+ and EDGAR. Aurora Cannabis highlighted that misinformation about the acquisition was circulating on a news website, which the company refuted. Despite these denials, a separate report mentioned a $215 million cash-and-stock deal by Aurora to acquire MedLeaf, but Aurora’s public statements contradict this claim, indicating no such transaction has been agreed upon. Aurora Cannabis continues to be a major player in the global medical cannabis market, serving regions including Canada, Europe, Australia, and New Zealand, with a broad portfolio of brands and a commitment to innovation and quality. Investors are advised to rely on Aurora's official disclosures for accurate information about the company's business activities.